Merck & Company, Inc. · NYSE:MRK
Merck & — Shareholder Meeting (May 2021)
25 slides from Merck &'s shareholder meeting presentation, May 25, 2021
Slide 1: Annual Meeting of Shareholders
Annual Meeting of Shareholders May 25, 2021
Slide 2: Forward-looking statement
Proprietary Forward-looking statement This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the
Slide 3: Annual Meeting of Shareholders
Annual Meeting of Shareholders May 25, 2021
Slide 4: Board of directors
Proprietary Board of directors Leslie A. Brun Mary Ellen Coe Pamela J. Craig Kenneth C. Frazier Thomas H. Glocer Risa J. Lavizzo- Paul B. Rothman, Patricia F. Russo Christine E. Seidman, Inge G. Thulin Mourey, M.D. M.D. M.D. Kathy J. Warden Peter C. Wendell Stephen L. Mayo, Ph.D.
Slide 5: Retiring board member
Proprietary Retiring board member Thomas R. Cech, Ph.D.
Slide 6: Executive committee
Proprietary Executive committee Kenneth C. Frazier Robert M. Davis Sanat Chattopadhyay Frank Clyburn Richard R. DeLuca Jr. Julie L. Gerberding, M.D., Dean Y. Li, M.D., Caroline Litchfield M.P.H. Ph.D. Steven C. Mizell David Williams Jennifer Zachary
Slide 7: Merck
€ MERCK
Slide 8: Merck's vision and mission: to save and improve lives
Merck’s vision and mission: to save and improve lives
Slide 9: COVID-19 response
COVID-19 response
Slide 10: COVID-19 therapeutic developments & collaborations
COVID-19 therapeutic developments & collaborations
Slide 11: Full-year 2020 highlights
Proprietary Full-year 2020 highlights Pharmaceutical sales Animal Health sales Merck FY 2020 WORLDWIDE SALES $43.0B $4.7B 3% growth 7% growth $48.0B 4% ex-exchange 10% ex-exchange Key drivers Key drivers STRONG GROWTH FROM DRIVEN BY THE ACQUISITION OF 2% growth KEYTRUDA, LYNPARZA, LENVIMA, ANTELLIQ
Slide 12: Merck
€ MERCK
Slide 13: Slide 13
Slide 14: Merck
€ MERCK
Slide 15: Organon spinoff timeline
March 11, 2020 February 1, 2021 March 17, 2021 April 22, 2021 June 2, 2021 NewCo Named Organon operates Form 10 Filing Organon financing Separation of Organon & Co. as company-in-a- complete Organon complete company February 5, 2020 March 17, 2021 March 30, 2021 May 3, 2021 June 3, 2021 Announcement
Slide 16: Merck
€ MERCK
Slide 17: Research and development highlights
Research and development highlights Annual Meeting of Shareholders May 25, 2021 Dean Y. Li
Slide 18: Building on a legacy of breakthrough science & innovation
Proprietary Building on a legacy of breakthrough science & innovation Authored >1500 publications; Filed 114 patents
Slide 19: Notable approvals in 2020
Proprietary Notable approvals in 2020 KEYTRUDA (7), LYNPARZA (2), KOSELUGO, GARDASIL 9 and RECARBRIO KEYTRUDA (2) and LENVIMA LYNPARZA (3) KEYTRUDA (2), LYNPARZA (3) and SILGARD9 ERVEBO approved in DRC, Burundi, Ghana and Zambia
Slide 20: Progressing molnupiravir as quickly as possible
Proprietary Progressing molnupiravir as quickly as possible Proceed to Phase 3 for outpatient population (MOVe-Out) • Focus on early treatment in Initiate a post-exposure Phase 2 data in hand high-risk subjects prophylaxis study for from MOVe-Outpatient • Study site locations focus on household cont
Slide 21: Multiple anticipated approvals for 2021
Proprietary Multiple anticipated approvals for 2021 New molecular entity Regulatory status Therapeutic area VERQUVO APPROVED Chronic heart failure (January) in adults 15-Valent pneumo- Target action: Pneumococcal conjugate vaccine July disease (adults) Belzutifan Target action: Von Hippel-Lindau Sep
Slide 22: Thank you
€ MERCK INVENTING FOR LIFE Thank you
Slide 23: Merck
€ MERCK
Slide 24: Board of directors
Proprietary Board of directors Leslie A. Brun Mary Ellen Coe Pamela J. Craig Kenneth C. Frazier Thomas H. Glocer Risa J. Lavizzo- Paul B. Rothman, Patricia F. Russo Christine E. Seidman, Inge G. Thulin Mourey, M.D. M.D. M.D. Kathy J. Warden Peter C. Wendell Stephen L. Mayo, Ph.D.
Slide 25: Merck
€ MERCK